ApconiX Welcomes Dr Steffen Ernst

ApconiX is delighted to welcome Dr Steffen Ernst to our team, as the company begins its international expansion with the formation of its Swedish subsidiary, ApconiX AB.

Steffen has worked in preclinical and clinical safety for over 20 years with Hoechst-Schering, Boehringer-Ingelheim, AstraZeneca, Pfizer and Ipsen, holding various pre-clinical and clinical positions of ever-increasing responsibility up to clinical Vice President.  He has extensive, multidisciplinary experience in the international pharmaceutical industry working in early drug discovery to marketed product support as well as in and outbound licensing.

Steffen attended Medical School in Germany and has an active Swedish license to practice with a background in anaesthesiology.  His career covers the entire pharma industry value chain from pre-clinical target identification to externalisation of marketed products at the end of exclusivity.  Steffen is particularly experienced in Discovery and Regulatory Toxicology, Early Clinical Development, Translational/ Safety Medicine and Pharmacovigilance.  His therapeutic areas of interest include oncology, respiratory, cardiovascular, endocrinology, metabolism, pain, neuroscience and primary care indications.

Steffen’s passion lays in the strategic management and support of pre-clinical to clinical transitions including regulatory agency interactions such as Scientific Advice at the EMA and FDA.

“As an enthusiastic pharmaceutical industry professional with a passion for organisation and people development, I am looking forward to working with the ApconiX team of highly experienced scientists and bringing all our expertise to helping the developing biotech industry in Sweden and throughout the world,” added Steffen.

Dr Richard Knight, Director and Co-Founder of ApconiX, commented, “Everyone at ApconiX is excited about this expansion into Scandinavia.  Having worked with Steffen for many years, his depth and breadth of experience in drug development will be a great asset to the team.  Having now established a presence in Gothenburg, we will continue to grow and help our customers around the world make better decisions on drug safety.”

By |2019-02-07T16:37:23+00:00February 6th, 2019|Toxicology, Careers|Comments Off on ApconiX Welcomes Dr Steffen Ernst

About the Author:

Dr Michael Morton, PhD, Director and Cofounder, ApconiX, UK, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Mike graduated from the University of Wolverhampton with a degree in Biomedical Sciences and then aspiration to work in hospital pathology. Having finished his Sandwich placement in Clinical Biochemistry at Sandwell Hospital and Mike subsequently gained a MSc in Clinical Biochemistry from the University of Manchester and carried out research into porphyrin metabolism. Moving to the University of Leeds, Mike completed his PhD in Pharmacology at researching adenosine receptor expression in the rat kidney . Mike was introduced to ion channels as a Post-Doc at Leeds and Yale University, patching with the likes of Fred Sigworth and Steve Hebert, then joined the Global Ion Channel Initiative at AstraZeneca. Mike worked at AstraZeneca for eight years before founding ApconiX with Professor Ruth Roberts and Dr Richard Knight. Mike has a serious passion for ion channels. And he’s very good at them . He is a serious scientist (with a serious sense of humour) who wants to make sure that every customer understands the consequences of the results he obtains and works with his colleagues to ensure a better decision is made on drug safety.